Page 67 - GPD-3-3

Gene & Protein in Disease Amino acid metabolism in neurodegeneration

doi: 10.1152/physrev.00001.2017 doi: 10.1042/BST20190331
39. Pålsson-McDermott EM, O’Neill LAJ. Targeting 51. Costa-Mattioli M, Gobert D, Harding H, et al. Translational
immunometabolism as an anti-inflammatory strategy. Cell control of hippocampal synaptic plasticity and memory
Res. 2020;30(4):300-314. by the eIF2alpha kinase GCN2. Nature. 2005;436(7054):
doi: 10.1038/s41422-020-0291-z 1166-1173.
40. Kominsky DJ, Campbell EL, Colgan SP. Metabolic shifts doi: 10.1038/nature03897
in immunity and inflammation. J Immunol. 2010;184(7): 52. Krukowski K, Nolan A, Frias ES, et al. Small molecule
4062-4068. cognitive enhancer reverses age-related memory decline in
doi: 10.4049/jimmunol.0903002 mice. eLife. 2020;9:62048.
doi: 10.7554/eLife.62048
41. Kelly B, Pearce EL. Amino assets: How amino acids support
immunity. Cell Metab. 2020;32(2):154-175. 53. Castellano F, Molinier-Frenkel V. Control of T-cell activation
and signaling by amino-acid catabolizing enzymes. Front
doi: 10.1016/j.cmet.2020.06.010
Cell Dev Biol. 2020;8:613416.
42. Dato S, Hoxha E, Crocco P, Iannone F, Passarino G, Rose G.
Amino acids and amino acid sensing: Implication for aging doi: 10.3389/fcell.2020.613416
and diseases. Biogerontology. 2019;20(1):17-31. 54. Correale J. Immunosuppressive amino-acid catabolizing
doi: 10.1007/s10522-018-9770-8 enzymes in multiple sclerosis. Front Immunol.
2020;11:600428.
43. Liu GY, Sabatini DM. mTOR at the nexus of nutrition,
growth, ageing and disease. Nat Rev Mol Cell Biol. doi: 10.3389/fimmu.2020.600428
2020;21(4):183-203. 55. Orsini H, Araujo LP, Maricato JT, et al. GCN2 kinase
doi: 10.1038/s41580-019-0199-y plays an important role triggering the remission phase of
experimental autoimmune encephalomyelitis (EAE) in
44. Castilho BA, Shanmugam R, Silva RC, Ramesh R, mice. Brain Behav Immun. 2014;37:177-186.
Himme BM, Sattlegger E. Keeping the eIF2 alpha kinase
Gcn2 in check. Biochim Biophys Acta. 2014;1843(9): doi: 10.1016/j.bbi.2013.12.012
1948-1968. 56. Sundrud MS, Koralov SB, Feuerer M, et al. Halofuginone
doi: 10.1016/j.bbamcr.2014.04.006 inhibits TH17 cell differentiation by activating the
amino acid starvation response. Science. 2009;324(5924):
45. Lee DY. Roles of mTOR signaling in brain development. Exp 1334-1338.
Neurobiol. 2015;24(3):177-185.
doi: 10.1126/science.1172638
doi: 10.5607/en.2015.24.3.177
57. Dello Russo C, Lisi L, Feinstein DL, Navarra P. mTOR kinase,
46. Lei G, Zhuang L, Gan B. mTORC1 and ferroptosis: a key player in the regulation of glial functions: Relevance
Regulatory mechanisms and therapeutic potential. Bioessays. for the therapy of multiple sclerosis. Glia. 2013;61(3):
2021;43(6):e2100093. 301-311.
doi: 10.1002/bies.202100093 doi: 10.1002/glia.22433
47. Takei N, Nawa H. mTOR signaling and its roles in normal 58. Fitzgerald KC, Smith MD, Kim S, et al. Multi-omic
and abnormal brain development. Front Mol Neurosci. evaluation of metabolic alterations in multiple sclerosis
2014;7:28. identifies shifts in aromatic amino acid metabolism. Cell Rep
doi: 10.3389/fnmol.2014.00028 Med. 2021;2(5):100424.
48. Perluigi M, Di Domenico F, Butterfield DA. mTOR signaling doi: 10.1016/j.xcrm.2021.100424
in aging and neurodegeneration: At the crossroad between 59. Rzepiński Ł, Kośliński P, Gackowski M, Koba M, Maciejek Z.
metabolism dysfunction and impairment of autophagy. Amino acid levels as potential biomarkers of multiple
Neurobiol Dis. 2015;84:39-49. sclerosis in elderly patients: Preliminary report. J Clin
doi: 10.1016/j.nbd.2015.03.014 Neurol. 2022;18(5):529-534.
49. Ryskalin L, Lazzeri G, Flaibani M, et al. mTOR- doi: 10.3988/jcn.2022.18.5.529
dependent cell proliferation in the brain. Biomed Res Int. 60. Tang Z, Liu L, Li Y, et al. Urinary metabolomics reveals
2017;2017:7082696. alterations of aromatic amino acid metabolism of
doi: 10.1155/2017/7082696 Alzheimer’s disease in the transgenic CRND8 mice. Curr
Alzheimer Res. 2016;13(7):764-776.
50. Masson GR. Towards a model of GCN2 activation. Biochem
Soc Trans. 2019;47(5):1481-1488. doi: 10.2174/1567205013666160129095340

Volume 3 Issue 3 (2024) 13 doi: 10.36922/gpd.3294